Author

Paul Taylor

Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial

2017 · Michele Maio, Arnaud Scherpereel, et al. · The Lancet Oncology · 424

Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trial

2019 · Giorgio V Scagliotti, Rabab Gaafar, et al. · The Lancet Respiratory Medicine · 168

Nintedanib Plus Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma: Phase II Results From the Randomized, Placebo-Controlled LUME-Meso Trial

2017 · Federica Grosso, Nicola Steele, et al. · Journal of Clinical Oncology · 143

EZH2 inhibitor tazemetostat in patients with relapsed or refractory, BAP1-inactivated malignant pleural mesothelioma: a multicentre, open-label, phase 2 study

2022 · Marjorie G Zauderer, Peter W Szlosarek, et al. · The Lancet Oncology · 136

Maintenance Defactinib Versus Placebo After First-Line Chemotherapy in Patients With Merlin-Stratified Pleural Mesothelioma: COMMAND—A Double-Blind, Randomized, Phase II Study

2019 · Dean A. Fennell, Paul Baas, et al. · Journal of Clinical Oncology · 132

Extended pleurectomy decortication and chemotherapy versus chemotherapy alone for pleural mesothelioma (MARS 2): a phase 3 randomised controlled trial

2024 · Eric Lim, David Waller, et al. · The Lancet Respiratory Medicine · 131

Mesothelioma and Radical Surgery 2 (MARS 2): protocol for a multicentre randomised trial comparing (extended) pleurectomy decortication versus no (extended) pleurectomy decortication for patients with malignant pleural mesothelioma

2020 · Eric Lim, Liz Darlison, et al. · BMJ Open · 80

PDF

NGR-hTNF in combination with best investigator choice in previously treated malignant pleural mesothelioma (NGR015): a randomised, double-blind, placebo-controlled phase 3 trial

2018 · Vanesa Gregorc, Rabab M Gaafar, et al. · The Lancet Oncology · 78

Single-Agent Pemetrexed for Chemonaïve and Pretreated Patients with Malignant Pleural Mesothelioma: Results of an International Expanded Access Program

2008 · Paul Taylor, Bruno Castagneto, et al. · Journal of Thoracic Oncology · 69

PDF

Anetumab ravtansine versus vinorelbine in patients with relapsed, mesothelin-positive malignant pleural mesothelioma (ARCS-M): a randomised, open-label phase 2 trial

2022 · Hedy L Kindler, Silvia Novello, et al. · The Lancet Oncology · 68

Phase III randomised trial of doxorubicin-based chemotherapy compared with platinum-based chemotherapy in small-cell lung cancer

2008 · S Baka, R Califano, et al. · British Journal of Cancer · 49

PDF

Tremelimumab as second- or third-line treatment of unresectable malignant mesothelioma (MM): Results from the global, double-blind, placebo-controlled DETERMINE study.

2016 · Hedy L. Kindler, Arnaud Scherpereel, et al. · Journal of Clinical Oncology · 45

Omitting elective nodal irradiation during thoracic irradiation in limited-stage small cell lung cancer – Evidence from a phase II trial

2011 · Rovel Colaco, Hamid Sheikh, et al. · Lung Cancer · 32

Active symptom control with or without oral vinorelbine in patients with relapsed malignant pleural mesothelioma (VIM): A randomised, phase 2 trial

2022 · Dean A. Fennell, Catharine Porter, et al. · EClinicalMedicine · 26

PDF

Prophylactic Cranial Irradiation for Limited-Stage Small-Cell Lung Cancer Patients: Secondary Findings From the Prospective Randomized Phase 3 CONVERT Trial

2018 · Antonin Levy, Cécile Le Péchoux, et al. · Journal of Thoracic Oncology · 20

PDF

ATOMIC-Meso: A randomized phase 2/3 trial of ADI-PEG20 or placebo with pemetrexed and cisplatin in patients with argininosuccinate synthetase 1-deficient non-epithelioid mesothelioma.

2017 · Peter Wojciech Szlosarek, Paul Baas, et al. · Journal of Clinical Oncology · 10

Phase III trial (NGR015) with NGR-hTNF plus best investigator choice (BIC) versus placebo plus BIC in previously treated patients with advanced malignant pleural mesothelioma (MPM).

2015 · Rabab M. Gaafar, Adolfo G. Favaretto, et al. · Journal of Clinical Oncology · 10

A study demonstrating users’ preference for the adapted-REQUITE patient-reported outcome questionnaire over PRO-CTCAE® in patients with lung cancer

2024 · Thomas Jordan, Thitikorn Nuamek, et al. · Frontiers in Oncology · 8

PL03.10 MARS 2: A Multicentre Randomised Trial Comparing (Extended) Pleurectomy Decortication versus No Radical Surgery for Mesothelioma

2023 · E. Lim, D. Waller, et al. · Journal of Thoracic Oncology · 8

PDF

Interleukin-2 in malignant pleural mesothelioma (and adenocarcinoma of the lung). The use of intrapleural and continuous intravenous infusions: preliminary results

1989 · N. Thatcher, P. Taylor, et al. · Cancer Treatment Reviews · 8

Service Evaluation of MyChristie-MyHealth, an Electronic Patient-Reported Outcome Measure Integrated Into Clinical Cancer Care

2024 · Lee A. Shipman, James Price, et al. · JCO Clinical Cancer Informatics · 7

C5-03: Open-label study of pemetrexed alone or in combination with a platinum for previously treated patients (pts) with malignant pleural mesothelioma (MPM): Outcomes from the International Expanded Access Program (EAP)

2007 · Ulrich Gatzemeier, Paul Taylor, et al. · Journal of Thoracic Oncology · 7

PDF

Evaluating niraparib versus active symptom control in patients with previously treated mesothelioma (NERO): a study protocol for a multicentre, randomised, two-arm, open-label phase II trial in UK secondary care centres

2023 · Dean Fennell, Daniel Griffiths, et al. · BMJ Open · 5

PDF

OA22.02 Nintedanib plus Pemetrexed/Cisplatin in Patients with MPM: Phase II Findings from the Placebo-Controlled LUME-Meso Trial

2017 · Federica Grosso, Nicola Steele, et al. · Journal of Thoracic Oncology · 4

Correlation between thymidylate synthetase (TS) expression and progression-free survival (PFS) in patients receiving pemetrexed (pem) for advanced NSCLC: A prospective study.

2012 · Marianne Nicolson, Keith M Kerr, et al. · Journal of Clinical Oncology · 4

Works count: 69

Citation count: 1,691

H-index: 15

I10-index: 17